Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

NCT00502164 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-01-21

No results posted yet for this study

Summary

A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.

Conditions

  • Advanced Prostate Adenocarcinoma

Interventions

DRUG

AZD2171

Sponsors & Collaborators

Principal Investigators

  • Nick Botwood, BSc, MBBS, MRCP, MFPM · AstraZeneca

  • Eric Small, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00502164 on ClinicalTrials.gov